Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medicare Part D Spending On Established Brands Grew 62% Despite Rebates

Executive Summary

HHS Office of Inspector General traces reimbursement, pricing, rebating and utilization patterns for established brands from 2011 to 2015.

You may also be interested in...



Medicare Part D Spending Projected To Decline in 2018 As Rebates Increase

Part D plans project rebates will increase to 25.3% of total drug costs in their bids for the 2018 benefit year, the recently-released Medicare Trustees Report notes.

Trump Drug Pricing Plan Includes Part D Surprises, Challenges PBM Business Model

The reform 'blueprint' might actually live up to its hype.

ICER Partnering With Aetion To Scale Up Use Of RWE In Value Assessments

Aetion is also working with the US Food and Drug Administration and a number of biopharma companies on projects involving use of real-world evidence.

Topics

Related Companies

UsernamePublicRestriction

Register

PS123233

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel